aspect
of
partnership)
→
CapableOf
→
continue to develop transmission-blocking vaccine
Typicality: | 0.271 |
Saliency: | 0.051 |
partner → continue to develop → transmission-blocking vaccine | 4 |
negative | neutral | positive |
0.037 | 0.788 | 0.175 |
Raw frequency | 4 |
Normalized frequency | 0.051 |
Modifier score | 0.500 |
Perplexity | 159.437 |